Maze Therapeutics (MAZE) said late Thursday it priced its upsized initial public offering of about 8.8 million shares at $16 per share for gross proceeds of $140 million.
In addition, Maze Therapeutics said it has granted the underwriters a 30-day option to purchase up to an additional 1.3 million shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq on Friday under the symbol 'MAZE.'
The offering is expected to close on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.